Hospital for Special Surgery, New York
hss.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
224
Active
53
Phase 3
10
Total enrollment
44,848
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Abaloparatide | — | — | — | — | 2 | ||
| Low-dose PRP | — | — | — | — | — | 1 | |
| High-dose PRP | — | — | — | — | — | 1 | |
| Concentrated Bone Marrow Aspirate | — | — | — | — | — | 1 | |
| Lidocaine 2% | — | — | — | — | — | 1 | |
| Lidocaine 1% | — | — | — | — | — | 1 | |
| Bupivacaine 0.25% | — | — | — | — | — | 1 | |
| Bupivacaine 0.5% | — | — | — | — | — | 1 | |
| Intralipid, 20% Intravenous | — | — | — | — | — | 1 | |
| Bupivacaine, Dexamethasone in Adductor Canal Block | — | — | — | — | — | 1 | |
| Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block | — | — | — | — | — | 1 | |
| Dextrose 5% in water | — | — | — | — | — | 1 | |
| Denosumab | — | — | — | — | — | 1 | |
| Risedronate Oral | — | — | — | — | — | 1 | |
| Low dose naltrexone | — | — | — | — | — | 1 | |
| Hydrocortisone | — | — | — | — | 4 | ||
| Depo-Medrol 40Mg/Ml Suspension for | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| General anesthetic | — | — | — | — | — | 1 | |
| SA + ESP | — | — | — | — | — | 1 | |
| Tranexamic Acid 100 MG/ML | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | 3 | ||
| Belimumab | — | — | — | — | — | 2 | |
| MMF | — | — | — | — | — | 1 | |
| NKX019 | — | — | — | — | — | 1 | |
| Cyclophosphamide LD | — | — | — | — | — | 1 | |
| E-CEL UVEC | — | — | — | — | — | 1 | |
| dalfampridine | — | — | — | — | — | 1 | |
| ONT01 is a small molecule CD11b modulator. | — | — | — | — | — | 1 | |
| Bone Marrow Aspirate | — | — | — | — | — | 1 |
Next readouts
- 2026-05
- 2026-06-30
- 2026-07
- 2026-08
- 2026-09
- 2026-09-01
- 2026-09-01
- 2026-10
- 2026-10
- 2026-12
Top conditions
- Opioid Use13
- Pain9
- Knee Osteoarthritis9
- Pain, Postoperative8
- Osteoarthritis7
- Postoperative Pain6
- Total Knee Arthroplasty6
- Osteoarthritis, Knee5
Frequently asked questions about Hospital for Special Surgery, New York
- How many clinical trials does Hospital for Special Surgery, New York have on ClinicalTrials.gov?
- Hospital for Special Surgery, New York is listed as the lead sponsor on 224 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hospital for Special Surgery, New York's trials are in Phase 3?
- 10 of Hospital for Special Surgery, New York's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does Hospital for Special Surgery, New York focus on?
- Hospital for Special Surgery, New York's most-studied conditions on ClinicalTrials.gov are Opioid Use, Pain, Knee Osteoarthritis, Pain, Postoperative, Osteoarthritis.
- When are Hospital for Special Surgery, New York's next clinical trial readouts?
- Hospital for Special Surgery, New York has 10 upcoming primary-completion readouts tracked here; the soonest is “Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)”, expected around 2026-05.